Omocom Raises $5.3M Series

Neko Health

Neko Health is a healthcare technology company co-founded in 2018 by Swedish engineer Hjalmar Nilsonne and Spotify founder Daniel Ek. ‍ Our vision is to provide healthcare that’s proactive instead of reactive – so that people can live longer, healthier lives. By combining proprietary technology and thoughtful design with best-in-class clinical care and research, Neko has pioneered an affordable preventive health scan unlike any other.

WelloWork

WelloWork AB is a Sweden-based health technology company founded in February 2024 by a team affiliated with leading scientific institutions in Sweden and the UK. Our mission is to redefine workplace health and longevity, helping organizations build environments where employees can thrive — mentally, physically, and professionally. ✨ From this foundation, we developed two spin-off products: WelloWize – Human Resource Assessment (cognitive & technical skill assessment). WelloRise – Human Resource Education (daily micro-learning to improve cognitive & communication skills). At WelloWork, we combine longevity science, digital health innovation, and workplace expertise to empower both employees and employers with lasting solutions.

PharmNovo

PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor. PN6047 is Phase II ready!